Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2576–2578. doi: 10.1128/aac.41.11.2576

In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.

J A Karlowsky 1, G A Harding 1, S A Zelenitsky 1, D J Hoban 1, A Kabani 1, T V Balko 1, M Turik 1, G G Zhanel 1
PMCID: PMC164168  PMID: 9371373

Abstract

In vitro killing by a new semisynthetic echinocandin, LY-303366, was characterized using clinical isolates of fluconazole-sensitive (Y58) and -resistant (Y180) Candida albicans as well as Candida glabrata (Y7) and Candida krusei (Y171). The 24-h kill curves for Y58 and Y180 demonstrated dose-independent killing of between 1 and 2 log10 with LY-303366 at concentrations of 0.1, 1, 10, 50, 100, and 1,000 times the MIC. Regrowth did not occur at 24 h with either C. albicans isolate at the aforementioned LY-303366 concentrations. At their MICs, LY-303366 and amphotericin B produced similar killing kinetics in cultures of Y58, Y180, Y7, and Y171, while all cultures exposed to fluconazole at its MIC demonstrated stasis or growth over 24 h.

Full Text

The Full Text of this article is available as a PDF (176.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Banerjee S. N., Emori T. G., Culver D. H., Gaynes R. P., Jarvis W. R., Horan T., Edwards J. R., Tolson J., Henderson T., Martone W. J. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991 Sep 16;91(3B):86S–89S. doi: 10.1016/0002-9343(91)90349-3. [DOI] [PubMed] [Google Scholar]
  2. Ernst M. E., Klepser M. E., Wolfe E. J., Pfaller M. A. Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp. Diagn Microbiol Infect Dis. 1996 Nov-Dec;26(3-4):125–131. doi: 10.1016/s0732-8893(96)00202-7. [DOI] [PubMed] [Google Scholar]
  3. Pfaller M., Wenzel R. Impact of the changing epidemiology of fungal infections in the 1990s. Eur J Clin Microbiol Infect Dis. 1992 Apr;11(4):287–291. doi: 10.1007/BF01962067. [DOI] [PubMed] [Google Scholar]
  4. Vanden Bossche H., Warnock D. W., Dupont B., Kerridge D., Sen Gupta S., Improvisi L., Marichal P., Odds F. C., Provost F., Ronin O. Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol. 1994;32 (Suppl 1):189–202. doi: 10.1080/02681219480000821. [DOI] [PubMed] [Google Scholar]
  5. Zhanel G. G., Karlowsky J. A., Harding G. A., Balko T. V., Zelenitsky S. A., Friesen M., Kabani A., Turik M., Hoban D. J. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species. Antimicrob Agents Chemother. 1997 Apr;41(4):863–865. doi: 10.1128/aac.41.4.863. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES